WebPinteon Therapeutics 4 years 9 months Vice President of Biology Mar 2024 - May 20241 year 3 months Senior Director of Biology Jan 2024 - Feb 20242 years 2 months Director of Biology Sep 2024 -... WebJan 17, 2024 · H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in …
Cerebral Autoregulatory Function Before, During, and After …
WebJan 28, 2024 · Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development … WebMost recently, she was Executive Vice President and Chief Development Officer at Zogenix, Inc., a rare disease company, where she led successful Phase 3 development programs … dr greenbaum boynton beach fl
Michael Ahlijanian - Chief Scientific Officer - Pinteon ... - LinkedIn
WebFeb 1, 2024 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic … WebParticipants. We screened 606 people for the rs6971 polymorphism in the translocator protein (TSPO) gene.Of the 314 high-affinity binders, we studied 118 individuals that were across the aging and AD spectrum [79 cognitively unimpaired (CU), 23 with mild cognitive impairment (MCI), and 16 with AD dementia] with [18 F]AZD4694 Aβ PET, [18 F]MK6240 … dr greenbaum bariatric surgery